MediciNova, Inc. (MNOV)

1,3200 +0,0100 (+0,76%) Alla chiusura: 04:00PM EDT

MediciNova, Inc.

4275 Executive Square
Suite 300
La Jolla, CA 92037
United States
858 373 1500
https://www.medicinova.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 13

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Yuichi Iwaki M.D., Ph.D.	Co-Founder, President, CEO & Executive Director	907,26k	N/D	1950
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.	Chief Medical Officer & Director	649,05k	N/D	1966
Mr. Jason J. Kruger CPA	CFO & Principal Financial Officer	N/D	N/D	1978
Dr. David H. Crean M.B.A., Ph.D.	Chief Business Officer	N/D	N/D	1965
Mr. John O'Neil CPA	Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Governance aziendale

L'ISS Governance QualityScore di MediciNova, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 10; diritti degli azionisti: 5; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.